Biomet completes $1B debt offering; J&J wins 510(k) for adaptable surgical shears;

 @FierceMedDev: One way to address device hacking? A wrist-watch-like device that measures biometrics as a kind of security I.D. More  | Follow @FierceMedDev

 @MarkHFierce: CardioDx gained a crucial win: Medicare coverage for a coronary artery disease test. More | Follow @MarkHFierce

 @DamianFierce: In keeping with its plans to slim down, Boston Scientific is cutting 50 jobs in Ireland. More | Follow @DamianFierce

> The University of Minnesota's Medical Devices Center, which has filed 109 invention disclosures since is 2008 launch, is pursuing a $2.2 million expansion. Story

> Exact Sciences ($EXAS) is announcing plans for a public offering of common stock, likely sometime this month, according to a regulatory filing. Release

> Johnson & Johnson's Ethicon Endo-Surgery unit won a 510(k) clearance for new surgical shears that can adapt to handle tasks including dissection, sealing, transection and otomy creation. Release

> The European market for polymers in medical devices should surpass $1.3 billion by 2018 as the substance is increasingly used as a manufacturing ingredient, a new Frost & Sullivan report concludes. Release

> The 18th annual BIO-Europe conference will be held in Hamburg, Germany from Nov. 12-14, 2012 at the CCH Congress Center. The networking event is a major draw for medical device, biotech and pharmaceutical companies. Release

> Biomet ($BMET) says it has completed a $1 billion debt offering designed, in part, for refinancing purposes. Release

> Codman & Shurtleff snagged FDA approval for its Medstream Programmable Infusion System, an implantable infusion pump and catheter system designed to treat movement disorders caused by spinal injury. Item

> Diagnostics firm GenMark ($GNMK) reported a more than 300% revenue increase in Q2, crediting more placements and a burgeoning reagent business. More

> The Taiwanese medical device market is poised to top $3.3 billion this year and expand to $4 billion in 2013, one executive says. News

> Pfizer ($PFE) has obtained exclusive rights from Mylan to market and sell EpiPen products in Japan--devices that enable self-administered emergency treatment for life-threatening allergic reactions. Release

Biotech News

 @FierceBiotech: Fuji Pharma jumps into CMO game with $53.4M plant buy. More | Follow @FierceBiotech

 @JohnCFierce: Lundbeck's Phase II Alzheimer's drug that boosts cognition chemicals looks interesting. Harder to do deals now post-bapi? More | Follow @JohnCFierce

 @RyanMFierce: Lots of a Big Pharma news this week, mostly bad. How about some startup action? Good or bad. | Follow @RyanMFierce

> Novartis keeps U.K. respiratory unit after layoffs. Item

> Billionaire's biotech seals second deal with Synthetic Biologics. News

> AstraZeneca pulls the plug on sepsis drug after trial tanks. News

> Infinity Pharma axes 20% of jobs. Story

Pharma News

 @FiercePharma: Generics trounced Big Pharma's Q2 results. Who benefited? Our 11 Fastest-Growing Generics Companies. Special Report | Follow @FiercePharma

> Lundbeck eyes Alzheimer's partners as H1 sales stumble. Article

> DoJ hasn't given up on prosecuting execs for pharma misdoings. More

> Dissatisfied by buyout bids, Warner Chilcott opts for $1B dividend instead. Story

Biomarkers News

> Faster BRCA mutation identification could help families at risk. Story

> Prostate gene deficit could boost tumor growth. Item

> Brain signals when 'Special K' will do the trick. More

> Researchers find East Asian TKI resistance gene. Article

Drug Delivery News

> U.S. submission for Durect's Posidur is in the works. More

> Pluristem PLX cells turn around near fatal bone marrow failure. Article

> Endocyte's kidney conjugates get right to the spot. Story

> Swimming microbots could deliver drugs. Item

> Talon pins its hopes on Marqibo FDA approval. Report

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.